Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.

  title={Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.},
  author={Annamaria Colao and Antonella di Sarno and Maria Luisa Landi and Sossio Cirillo and F Sarnacchiaro and G Facciolli and Rosario Pivonello and Marielda Cataldi and Bartolomeo Merola and Lucio Annunziato and Gaetano Lombardi},
  journal={The Journal of clinical endocrinology and metabolism},
  volume={82 11},
Cabergoline (CAB), a long-lasting dopamine-agonist, specific for the D2 receptor, is effective in normalizing serum PRL levels in most patients with microprolactinoma or idiopathic hyperprolactinemia. Because few data are presently available on the effects of CAB treatment in macroprolactinomas, the aim of this open-label study was to investigate whether this drug was effective in producing tumor shrinkage, as well as in normalizing PRL levels. Twenty-three patients with macroprolactinoma… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 46 extracted citations

Macroprolactinoma: a diagnostic and therapeutic update.

QJM : monthly journal of the Association of Physicians • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…